Monofunctional Polyoxazoline Derivatives for Stable Bioconjugation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current polyoxazoline polymers face challenges in producing monofunctional derivatives with stable active functional groups for conjugation to target molecules, leading to issues with hydrolytic stability and immunogenicity, and they often have high polydispersity and impurities, limiting their use in pharmaceutical applications.
Innovation Solution
The development of monofunctional polyoxazoline derivatives with a range of active functional groups, synthesized using novel methods that minimize side reactions and impurities, allowing for hydrolytically stable conjugates with target molecules, such as proteins and peptides, and the use of enzymatic methods for conjugation to enhance stability and reduce immunogenicity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Adaptability or versatility
If conventional polyoxazoline polymers are used for conjugation to target molecules, then conjugation capability is provided, but hydrolytic stability deteriorates due to unstable active functional groups
Solution Approach 1:
The patent changes the chemical parameter of the active functional group from conventional unstable groups (such as carboxylic acids or hydroxyls) to activated ester groups (such as NHS esters, SCS esters, or HOBt esters). This parameter change transforms the functional group's reactivity profile, enabling it to be sufficiently stable during storage and circulation in the body while remaining reactive toward amine groups on target molecules like proteins and peptides, thus resolving the contradiction between conjugation capability and hydrolytic stability.
2Adaptability or versatility
If conventional polyoxazoline polymers are used, then conjugation is possible, but immunogenicity increases due to unstable functional groups and impurities
Solution Approach 1:
The patent changes the chemical stability parameter of the active functional group to activated esters, which are resistant to non-specific hydrolysis and oxidation. This reduces the generation of degradation impurities that could act as haptens and trigger immune responses. Additionally, the improved stability prevents the formation of unwanted byproducts during storage and in vivo circulation, thereby reducing immunogenicity while maintaining conjugation capability.
3Ease of manufacture
If conventional synthesis methods are used, then polyoxazoline derivatives are produced, but manufacturing precision deteriorates due to high polydispersity and impurities
Solution Approach 1:
The patent changes the synthesis parameter by employing controlled polymerization conditions and purification protocols that minimize side reactions and ensure uniform chain lengths. The use of activated ester groups allows for cleaner reactions with fewer byproducts, and the patent describes specific purification steps that remove residual monomers and side-products, thereby achieving high manufacturing precision with low polydispersity and high homogeneity while maintaining ease of manufacture.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The approach results in polyoxazoline conjugates with improved stability, reduced immunogenicity, and increased half-life in vivo, enabling more effective and prolonged activity of biopharmaceuticals like erythropoietin, while maintaining biological activity and reducing the need for frequent administration.
Implementation Method 1
the use of enzymatic methods for conjugation to enhance stability and reduce immunogenicity
Data Source
AI summary
The present disclosure provides POZ derivatives having a range of active functional groups allowing conjugation of POZ derivatives to a variety of target molecules under a wide range of reaction conditions to produce a hydrolytically stable target molecule-POZ conjugate. Furthermore, the present disclosure provides novel methods of synthesis for the disclosed POZ derivatives and hydrolytically stable target molecule-POZ conjugates created using the disclosed terminally activated monofunctional POZ derivatives. In one embodiment, the POZ derivative is a terminally activated monofunctional POZ derivative.